<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084708</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365546</org_study_id>
    <secondary_id>RPCI-RPC-0207</secondary_id>
    <nct_id>NCT00084708</nct_id>
  </id_info>
  <brief_title>Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Calcitriol may help tumor cells develop into normal cells. Dexamethasone may&#xD;
      increase the effectiveness and decrease the side effects of gefitinib and calcitriol.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when&#xD;
      given together with gefitinib or when given together with gefitinib and dexamethasone in&#xD;
      treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD), toxic effects, and tolerability of&#xD;
           calcitriol alone and in combination with gefitinib with or without dexamethasone in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of these regimens in these patients.&#xD;
&#xD;
        -  Determine any tumor responses in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of calcitriol.&#xD;
&#xD;
        -  Stage 1: Patients receive calcitriol IV over 1 hour on days 1, 15, and 22 and oral&#xD;
           gefitinib once daily on days 8-28 during course 1. For all subsequent courses, patients&#xD;
           receive calcitriol IV over 1 hour on days 1, 8, 15, and 22 and oral gefitinib once daily&#xD;
           on days 1-28. Courses repeat every 28 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of calcitriol with a fixed dose of gefitinib&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Stage 2: Patients receive calcitriol (beginning at 1 dose level below the MTD determined&#xD;
           in stage 1) and gefitinib as in stage 1. Patients also receive oral dexamethasone once&#xD;
           on the day before and twice on the day of each dose of calcitriol.&#xD;
&#xD;
      Cohorts 3-6 patients receive escalating doses of calcitriol with fixed doses of gefitinib and&#xD;
      dexamethasone until the MTD is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-36 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcitriol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
               -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  No unstable or uncompensated hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No prior hypercalcemia&#xD;
&#xD;
          -  No kidney, ureteral, or bladder stones within the past 10 years&#xD;
&#xD;
          -  No unstable or uncompensated renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 30%&#xD;
&#xD;
          -  No heart failure or significant heart disease&#xD;
&#xD;
          -  No significant arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No other unstable or uncompensated cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
               -  Chronic, stable, asymptomatic, radiographic changes allowed&#xD;
&#xD;
          -  No other unstable or uncompensated respiratory disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after study&#xD;
             treatment&#xD;
&#xD;
          -  Able to receive oral medication&#xD;
&#xD;
          -  Willing to have serial skin biopsies&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to study drugs or other agents used in this study&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other severe or uncontrolled systemic disease or concurrent illness that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  No other significant clinical disorder or laboratory finding that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No other concurrent systemic glucocorticoid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
          -  No prior nephrectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior anticancer therapy&#xD;
&#xD;
          -  More than 30 days since prior non-approved or investigational drugs&#xD;
&#xD;
          -  More than 7 days since prior thiazides&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Calcium supplements&#xD;
&#xD;
               -  Thiazides&#xD;
&#xD;
               -  Digoxin&#xD;
&#xD;
          -  No other concurrent investigational or commercial anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Marwan Fakih, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

